BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pivonello C, Patalano R, Solari D, Auriemma RS, Frio F, Vitulli F, Grasso LFS, Di Cera M, De Martino MC, Cavallo LM, Cappabianca P, Colao A, Pivonello R. Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting. Endocrine 2018;62:663-80. [PMID: 30066286 DOI: 10.1007/s12020-018-1677-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Grzywa TM, Klicka K, Rak B, Mehlich D, Garbicz F, Zieliński G, Maksymowicz M, Sajjad E, Włodarski PK. Lineage-dependent role of miR-410-3p as oncomiR in gonadotroph and corticotroph pituitary adenomas or tumor suppressor miR in somatotroph adenomas via MAPK, PTEN/AKT, and STAT3 signaling pathways. Endocrine 2019;65:646-55. [PMID: 31165412 DOI: 10.1007/s12020-019-01960-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
2 Oliveira HA, Bueno AC, Pugliesi RS, da Silva Júnior RMP, de Castro M, Martins CS. PI3K inhibition by BKM120 results in anti-proliferative effects on corticotroph tumor cells. J Endocrinol Invest 2022. [PMID: 34988938 DOI: 10.1007/s40618-021-01735-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ilie MD, Lasolle H, Raverot G. Emerging and Novel Treatments for Pituitary Tumors. J Clin Med 2019;8:E1107. [PMID: 31349718 DOI: 10.3390/jcm8081107] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
4 Nakano-Tateno T, Lau KJ, Wang J, McMahon C, Kawakami Y, Tateno T, Araki T. Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors. Front Endocrinol (Lausanne) 2021;12:624686. [PMID: 33841328 DOI: 10.3389/fendo.2021.624686] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Lamb LS, Sim HW, McCormack AI. Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature-"Are We There Yet?". Cancers (Basel) 2020;12:E308. [PMID: 32012988 DOI: 10.3390/cancers12020308] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
6 Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, Brue T. Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol 2021;17:671-84. [PMID: 34493834 DOI: 10.1038/s41574-021-00550-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 15.0] [Reference Citation Analysis]